Abiopharma

GALAPAGOS NV (GLPG)

Symbol	GLPG
Name	GALAPAGOS NV
Sector	HEALTH CARE
Region	Europe
Industry	Pharmaceutical Preparations
Address	GEN DE WITTELAAN L11 A3, 2800 MECHELEN, C9 00000
Telephone	3215342900
Fax	—
Email	—
Website	https://www.glpg.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001421876
Description	Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The companys product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohns disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis. Additional info from NASDAQ: Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The companys product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohns disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

2026-05-08 17:21

New Form 424B3 - Lakefront Biotherapeutics NV Filed: 2026-05-08 AccNo: 0001193805-26-000582 Size: 178 KB

2026-05-08 07:25

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: Galapagos NV - American Depositary Shares.

2026-05-08 07:25

NASDAQ traded attribute type Security_Name was changed. Previous value: Galapagos NV - American Depositary Shares. New value: Galapagos NV - American Depositary Shares.

2026-05-08 07:25

NASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: Galapagos NV - American Depositary Shares.

2026-05-08 07:25

Galapagos NV - American Depositary Shares (GLPG) was removed from the exchange traded list

2026-05-06 20:01

Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-06 20:01

Galapagos rapporteert financiële resultaten over het eerste kwartaal van 2026 en geeft bedrijfsupdate

2026-05-06 20:01

Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update

2026-04-29 13:00

GALAPAGOS NV (GLPG) Files Form 6-K

2026-04-28 20:01

Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026

No clinical trials found for this company.

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Placebo, multiple ascending doses, oral suspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT02179502
GLPG1690, multiple ascending doses, oral suspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT02179502
Placebo single ascending doses	Other	Phase PHASE1	Healthy	COMPLETED	NCT02179502
GLPG1690 single ascending doses	Other	Phase PHASE1	Healthy	COMPLETED	NCT02179502
GLPG1837 1000 mg	Other	Phase PHASE1	Healthy	COMPLETED	NCT02562950
Midazolam	Other	Phase PHASE1	Healthy	COMPLETED	NCT02562950
GLPG1837 500 mg	Other	Phase PHASE1	Healthy	COMPLETED	NCT02562950
Placebo Oral Tablet	Other	Phase PHASE2	Psoriatic Arthritis	COMPLETED	NCT03101670
filgotinib	Other	Phase PHASE2	Psoriatic Arthritis	COMPLETED	NCT03101670
GLPG2737	Other	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03540524
GLPG2222	Other	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03540524
GLPG2451 dose regimen B	Other	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03540524
GLPG2451 dose regimen A	Other	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03540524
csDMARDs	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02873936
Placebo to match filgotinib	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02873936
Filgotinib	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02873936
Placebo	Other	Phase PHASE1	Plaque Psoriasis	COMPLETED	NCT04594928
GLPG3667	Other	Phase PHASE1	Plaque Psoriasis	COMPLETED	NCT04594928
Placebo	Other	Phase PHASE2	Osteoarthritis	COMPLETED	NCT03595618
GLPG1972	Other	Phase PHASE2	Osteoarthritis	COMPLETED	NCT03595618
Placebo	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT04577781
GLPG3970	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT04577781
Filgotinib	Other	Phase PHASE1	Bioavailability	COMPLETED	NCT06043739
GLPG0259	Other	Phase PHASE1	Healthy	COMPLETED	NCT01024517
GLPG0259 solution	Other	Phase PHASE1	Healthy	COMPLETED	NCT01024517
placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT01023321
GLPG0555	Other	Phase PHASE1	Healthy	COMPLETED	NCT01023321
placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT01208753
GLPG0555 aqueous	Other	Phase PHASE1	Healthy	COMPLETED	NCT01208753
GLPG0555	Other	Phase PHASE1	Healthy	COMPLETED	NCT01208753
GLPG0259 free base	Other	Phase PHASE1	Healthy	COMPLETED	NCT01322451
GLPG0259 fumarate	Other	Phase PHASE1	Healthy	COMPLETED	NCT01322451
GLPG0555 nanosuspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT01278095
GLPG0555 solid dispersion	Other	Phase PHASE1	Healthy	COMPLETED	NCT01278095
placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT01179581
GLPG0634	Other	Phase PHASE1	Healthy	COMPLETED	NCT01179581
Placebo (Part B)	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01211249
GLPG0259 (Part B)	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01211249
Placebo	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01211249
GLPG0259 oral capsule	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01211249
placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT01336244
GLPG0778	Other	Phase PHASE1	Healthy	COMPLETED	NCT01336244
placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT01278108
GLPG0778	Other	Phase PHASE1	Healthy	COMPLETED	NCT01278108
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT01397370
GLPG0492	Other	Phase PHASE1	Healthy	COMPLETED	NCT01397370
Methotrexate	Other	Phase PHASE1	Healthy	COMPLETED	NCT00989703
GLPG0259	Other	Phase PHASE1	Healthy	COMPLETED	NCT00989703
placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT00989703
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT01538420
GLPG0492	Other	Phase PHASE1	Healthy	COMPLETED	NCT01538420
GLPG0974	Other	Phase PHASE1	Healthy	COMPLETED	NCT01496937
GLPG0187 prodrug	Drug	Phase PHASE1	Healthy	COMPLETED	NCT01580644
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT01419990
GLPG0634	Other	Phase PHASE1	Healthy	COMPLETED	NCT01419990
GLPG0634	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01384422
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT01721980
GLPG0974	Other	Phase PHASE1	Healthy	COMPLETED	NCT01721980
GLPG0634 100mg capsule once a day for 10 days	Other	Phase PHASE1	Healthy	COMPLETED	NCT01665924
100 mg dose of [14C] GLPG0634	Other	Phase PHASE1	Healthy	COMPLETED	NCT01820806
Midazolam	Other	Phase PHASE1	Healthy	COMPLETED	NCT01798979
GLPG0634	Other	Phase PHASE1	Healthy	COMPLETED	NCT01798979
GLPG0187	Other	Phase PHASE1	Solid Tumors	COMPLETED	NCT01313598
Placebo	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01668641
GLPG0634	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01668641
200 mg GLPG0634 as tablets, fed	Other	Phase PHASE1	Healthy	COMPLETED	NCT01915667
200 mg GLPG0634 as tablets, fasted	Other	Phase PHASE1	Healthy	COMPLETED	NCT01915667
200 mg GLPG0634 as capsules, fasted	Other	Phase PHASE1	Healthy	COMPLETED	NCT01915667
Placebo, multiple ascending doses, oral suspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT01887106
GLPG1205, multiple ascending doses, oral suspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT01887106
Placebo single ascending doses, oral suspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT01887106
GLPG1205 single ascending doses, oral suspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT01887106
Placebo	Other	Phase PHASE2	Ulcerative Colitis	COMPLETED	NCT01829321
GLPG0974	Other	Phase PHASE2	Ulcerative Colitis	COMPLETED	NCT01829321
100 mg GLPG1205	Other	Phase PHASE1	Healthy	COMPLETED	NCT02143856
GLPG0634	Other	Phase PHASE1	Renal Impairment	COMPLETED	NCT02084199
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT02162355
GLPG0634 200 mg	Other	Phase PHASE1	Healthy	COMPLETED	NCT02162355
GLPG0634 100 mg	Other	Phase PHASE1	Healthy	COMPLETED	NCT02162355
GLPG0634 50 mg	Other	Phase PHASE1	Healthy	COMPLETED	NCT02162355
Placebo multiple doses	Other	Phase PHASE1	Healthy	COMPLETED	NCT02325037
GLPG1837 multiple ascending doses	Other	Phase PHASE1	Healthy	COMPLETED	NCT02325037
Placebo single dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT02325037
GLPG1837 single ascending doses	Other	Phase PHASE1	Healthy	COMPLETED	NCT02325037
500 mg GLPG1837 as oral tablet	Other	Phase PHASE1	Healthy	COMPLETED	NCT02562859
500 mg GLPG1837 as oral suspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT02562859
Placebo	Other	Phase PHASE2	Ulcerative Colitis	COMPLETED	NCT02337608
GLPG1205	Other	Phase PHASE2	Ulcerative Colitis	COMPLETED	NCT02337608
Cocktail of CYP450 substrates	Other	Phase PHASE1	Healthy	COMPLETED	NCT02623296
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT02623296
GLPG1205	Other	Phase PHASE1	Healthy	COMPLETED	NCT02623296
Placebo	Other	Phase PHASE2	Crohn's Disease	COMPLETED	NCT02048618
GLPG0634	Other	Phase PHASE2	Crohn's Disease	COMPLETED	NCT02048618
Placebo multiple doses	Other	Phase PHASE1	Healthy	COMPLETED	NCT02662452
GLPG2222 multiple doses	Other	Phase PHASE1	Healthy	COMPLETED	NCT02662452
Placebo single dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT02662452
GLPG2222 single dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT02662452
Placebo multiple doses	Other	Phase PHASE1	Healthy	COMPLETED	NCT02612246
GLPG1972 multiple ascending doses	Other	Phase PHASE1	Healthy	COMPLETED	NCT02612246
Placebo single dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT02612246
GLPG1972 single ascending doses	Other	Phase PHASE1	Healthy	COMPLETED	NCT02612246
GLPG1972 600 mg oral tablet fed	Other	Phase PHASE1	Osteoarthritis	COMPLETED	NCT02851485
GLPG1972 600 mg oral tablet fasted	Other	Phase PHASE1	Osteoarthritis	COMPLETED	NCT02851485
GLPG1972 600 mg oral solution fasted	Other	Phase PHASE1	Osteoarthritis	COMPLETED	NCT02851485
Methylprednisolone	Other	Phase PHASE2	Acute Exacerbation of Remitting Relapsing Multiple Sclerosis	TERMINATED	NCT01039103
PEG-liposomal prednisolone sodium phosphate	Other	Phase PHASE2	Acute Exacerbation of Remitting Relapsing Multiple Sclerosis	TERMINATED	NCT01039103
GLPG1837 dose 2	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT02690519
GLPG1837 dose 1	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT02690519
GLPG1837 dose 3	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT02707562
GLPG1837 dose 2	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT02707562
GLPG1837 dose 1	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT02707562
GLPG1205 250 loading dose and 50mg q.d. maintenance dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03102567
Placebo oral capsule	Other	Phase PHASE1	Healthy	COMPLETED	NCT03102567
GLPG1205 50mg q.d.	Other	Phase PHASE1	Healthy	COMPLETED	NCT03102567
GLPG1972	Other	Phase PHASE1	Healthy	COMPLETED	NCT03143725
GLPG1690	Other	Phase PHASE1	Healthy	COMPLETED	NCT03143712
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT02788721
GLPG2451 single dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT02788721
Combined Placebo multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03214614
GLPG2451/GLPG2222 multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03214614
Placebo multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03214614
GLPG2451 multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03214614
Placebo multiple intravenous administrations	Other	Phase PHASE1	Healthy	COMPLETED	NCT02739009
MOR106 multiple ascending doses, intravenous	Other	Phase PHASE1	Healthy	COMPLETED	NCT02739009
Placebo single ascending doses, intravenous	Other	Phase PHASE1	Healthy	COMPLETED	NCT02739009
MOR106 single ascending doses, intravenous	Other	Phase PHASE1	Healthy	COMPLETED	NCT02739009
Placebo	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03045523
GLPG2222 300 mg q.d.	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03045523
GLPG2222 150 mg q.d.	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03045523
Placebo	Other	Phase PHASE1	Osteoarthritis	COMPLETED	NCT03311009
GLPG1972 cohort 3	Other	Phase PHASE1	Osteoarthritis	COMPLETED	NCT03311009
GLPG1972 cohort 2	Other	Phase PHASE1	Osteoarthritis	COMPLETED	NCT03311009
GLPG1972 cohort 1	Other	Phase PHASE1	Osteoarthritis	COMPLETED	NCT03311009
GLPG2737 multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03410979
Placebo single dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03410979
GLPG2737 single dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03410979
GLPG2737 single dose	Other	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03450720
GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067/GLPG2222/GLPG2737 multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067/GLPG2222 Placebo multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067/GLPG2222 multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067 oral tablet	Other	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067 oral suspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT03128606
Placebo multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067 multiple dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03128606
Placebo single dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067 single dose	Other	Phase PHASE1	Healthy	COMPLETED	NCT03128606
Voriconazole	Other	Phase PHASE1	Healthy	COMPLETED	NCT03515382
Itraconazole	Other	Phase PHASE1	Healthy	COMPLETED	NCT03515382
GLPG1690	Other	Phase PHASE1	Healthy	COMPLETED	NCT03515382
Placebo	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03474042
GLPG2737	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03474042
GLPG3067 single dose	Other	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03589313
Placebo Oral Tablet	Other	Phase PHASE2	Ankylosing Spondylitis	COMPLETED	NCT03117270
filgotinib	Other	Phase PHASE2	Ankylosing Spondylitis	COMPLETED	NCT03117270
GLPG2222 400 mg	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03119649
GLPG2222 200 mg	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03119649
Placebo	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03119649
GLPG2222 100 mg	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03119649
GLPG2222 50 mg	Other	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03119649
[14C]-GLPG1690 capsules	Other	Phase PHASE1	Healthy	COMPLETED	NCT03787186
[14C]-GLPG1690 solution for infusion	Other	Phase PHASE1	Healthy	COMPLETED	NCT03787186
GLPG1690 film-coated tablets	Other	Phase PHASE1	Healthy	COMPLETED	NCT03787186
Placebo MAD	Other	Phase PHASE1	Healthy	COMPLETED	NCT03899909
GLPG3121 MAD	Other	Phase PHASE1	Healthy	COMPLETED	NCT03899909
Placebo SAD	Other	Phase PHASE1	Healthy	COMPLETED	NCT03899909
GLPG3121 SAD	Other	Phase PHASE1	Healthy	COMPLETED	NCT03899909
[14C]-GLPG1972 oral solution	Other	Phase PHASE1	Healthy	COMPLETED	NCT04136327
[14C]-GLPG1972 solution for infusion	Other	Phase PHASE1	Healthy	COMPLETED	NCT04136327
GLPG1972 film-coated tablets	Other	Phase PHASE1	Healthy	COMPLETED	NCT04136327
GLPG1972 - C	Other	Phase PHASE1	Healthy	COMPLETED	NCT04137341
GLPG1972 - B	Other	Phase PHASE1	Healthy	COMPLETED	NCT04137341
GLPG1972 - A	Other	Phase PHASE1	Healthy	COMPLETED	NCT04137341
Placebo	Other	Phase PHASE1	Healthy	TERMINATED	NCT03689829
MOR106	Other	Phase PHASE1	Healthy	TERMINATED	NCT03689829
Placebo	Other	Phase PHASE2	Atopic Dermatitis	TERMINATED	NCT03568071
MOR 106	Other	Phase PHASE2	Atopic Dermatitis	TERMINATED	NCT03568071
GLPG3312 FE MR	Other	Phase PHASE1	Healthy	COMPLETED	NCT03800472
GLPG3312 MR	Other	Phase PHASE1	Healthy	COMPLETED	NCT03800472
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT03800472
GLPG3312 IR	Other	Phase PHASE1	Healthy	COMPLETED	NCT03800472
Filgotinib placebo	Other	Phase PHASE2	Cutaneous Lupus Erythematosus	COMPLETED	NCT03134222
Lanraplenib placebo	Other	Phase PHASE2	Cutaneous Lupus Erythematosus	COMPLETED	NCT03134222
Filgotinib	Other	Phase PHASE2	Cutaneous Lupus Erythematosus	COMPLETED	NCT03134222
Lanraplenib	Other	Phase PHASE2	Cutaneous Lupus Erythematosus	COMPLETED	NCT03134222
Tirabrutinib placebo	Other	Phase PHASE2	Sjogren's Syndrome	COMPLETED	NCT03100942
Filgotinib placebo	Other	Phase PHASE2	Sjogren's Syndrome	COMPLETED	NCT03100942
Lanraplenib placebo	Other	Phase PHASE2	Sjogren's Syndrome	COMPLETED	NCT03100942
Tirabrutinib	Other	Phase PHASE2	Sjogren's Syndrome	COMPLETED	NCT03100942
Filgotinib	Other	Phase PHASE2	Sjogren's Syndrome	COMPLETED	NCT03100942
Lanraplenib	Other	Phase PHASE2	Sjogren's Syndrome	COMPLETED	NCT03100942
Placebo QD	Other	Phase PHASE2	Idiopathic Pulmonary Fibrosis	COMPLETED	NCT02738801
GLPG1690 600 mg QD	Other	Phase PHASE2	Idiopathic Pulmonary Fibrosis	COMPLETED	NCT02738801
Placebo	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01888874
GLPG0634	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01888874
Placebo	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01894516
GLPG0634	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01894516
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT04532567
GLPG1205	Other	Phase PHASE1	Healthy	COMPLETED	NCT04532567
Placebo	Other	Phase PHASE2	Atopic Dermatitis	TERMINATED	NCT03864627
MOR106	Other	Phase PHASE2	Atopic Dermatitis	TERMINATED	NCT03864627
Placebo to Match Filgotinib	Other	Phase PHASE3	Ankylosing Spondylitis	WITHDRAWN	NCT04483700
Filgotinib	Other	Phase PHASE3	Ankylosing Spondylitis	WITHDRAWN	NCT04483700
Placebo to Match Filgotinib	Other	Phase PHASE3	Ankylosing Spondylitis	WITHDRAWN	NCT04483687
Filgotinib	Other	Phase PHASE3	Ankylosing Spondylitis	WITHDRAWN	NCT04483687
Filgotinib	Other	Phase PHASE1	Rheumatoid Arthritis	COMPLETED	NCT03417778
Midazolam	Other	Phase PHASE1	Healthy	COMPLETED	NCT04736927
GLPG3667	Other	Phase PHASE1	Healthy	COMPLETED	NCT04736927
GLPG3970 tablet	Other	Phase PHASE1	Healthy	COMPLETED	NCT04708184
GLPG3970 oral solution	Other	Phase PHASE1	Healthy	COMPLETED	NCT04708184
GLPG1205 capsules	Other	Phase PHASE1	Healthy	COMPLETED	NCT04704739
[14C]-GLPG1205 solution for infusion	Other	Phase PHASE1	Healthy	COMPLETED	NCT04704739
GLPG1205 film-coated tablets	Other	Phase PHASE1	Healthy	COMPLETED	NCT04704739
PTM filgotinib	Other	Phase PHASE3	Ulcerative Colitis	COMPLETED	NCT02914522
Filgotinib	Other	Phase PHASE3	Ulcerative Colitis	COMPLETED	NCT02914522
Placebo	Other	Phase PHASE2	Systemic Sclerosis	COMPLETED	NCT03798366
GLPG1690	Other	Phase PHASE2	Systemic Sclerosis	COMPLETED	NCT03798366
GLPG4059 tablet	Other	Phase PHASE1	Healthy	TERMINATED	NCT04575818
Placebo	Other	Phase PHASE1	Healthy	TERMINATED	NCT04575818
GLPG4059 oral suspension	Other	Phase PHASE1	Healthy	TERMINATED	NCT04575818
Placebo to match MTX	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02886728
MTX	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02886728
Placebo to match filgotinib	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02886728
Filgotinib	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02886728
MTX	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02889796
Placebo to match adalimumab	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02889796
Adalimumab	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02889796
Placebo to match filgotinib	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02889796
Filgotinib	Other	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02889796
[14]GLPG3970 oral solution	Other	Phase PHASE1	Healthy	COMPLETED	NCT04907149
[14C]GLPG3970 solution for infusion	Other	Phase PHASE1	Healthy	COMPLETED	NCT04907149
GLPG3970 film-coated tablet	Other	Phase PHASE1	Healthy	COMPLETED	NCT04907149
Placebo to match filgotinib	Other	Phase PHASE2	Small Bowel Crohn's Disease	COMPLETED	NCT03046056
Filgotinib	Other	Phase PHASE2	Small Bowel Crohn's Disease	COMPLETED	NCT03046056
Placebo	Other	Phase PHASE2	Idiopathic Pulmonary Fibrosis	COMPLETED	NCT03725852
GLPG1205	Other	Phase PHASE2	Idiopathic Pulmonary Fibrosis	COMPLETED	NCT03725852
Placebo film-coated tablet	Other	Phase PHASE1	Systemic Lupus Erythematosus	TERMINATED	NCT04700267
GLPG3970 film-coated tablet	Other	Phase PHASE1	Systemic Lupus Erythematosus	TERMINATED	NCT04700267
Midazolam	Other	Phase PHASE1	Healthy	COMPLETED	NCT05030857
GLPG4716	Other	Phase PHASE1	Healthy	COMPLETED	NCT05030857
Prednisone	Other	Phase PHASE2	Noninfectious Uveitis	TERMINATED	NCT03207815
Placebo to match filgotinib	Other	Phase PHASE2	Noninfectious Uveitis	TERMINATED	NCT03207815
Filgotinib	Other	Phase PHASE2	Noninfectious Uveitis	TERMINATED	NCT03207815
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT04653467
GLPG4399 capsules	Other	Phase PHASE1	Healthy	COMPLETED	NCT04653467
GLPG4399 oral suspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT04653467
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT04976270
GLPG3667	Other	Phase PHASE1	Healthy	COMPLETED	NCT04976270
Placebo to match filgotinib	Other	Phase PHASE3	Psoriatic Arthritis	TERMINATED	NCT04115839
Filgotinib	Other	Phase PHASE3	Psoriatic Arthritis	TERMINATED	NCT04115839
GLPG1690	Other	Phase PHASE2	Systemic Sclerosis	TERMINATED	NCT03976648
Placebo to match filgotinib	Other	Phase PHASE2	Fistulizing Crohn's Disease	COMPLETED	NCT03077412
Filgotinib	Other	Phase PHASE2	Fistulizing Crohn's Disease	COMPLETED	NCT03077412
filgotinib	Other	Phase PHASE2	Psoriatic Arthritis	TERMINATED	NCT03320876
Placebo to match adalimumab	Other	Phase PHASE3	Psoriatic Arthritis	TERMINATED	NCT04115748
Placebo to match filgotinib	Other	Phase PHASE3	Psoriatic Arthritis	TERMINATED	NCT04115748
Adalimumab	Other	Phase PHASE3	Psoriatic Arthritis	TERMINATED	NCT04115748
Filgotinib	Other	Phase PHASE3	Psoriatic Arthritis	TERMINATED	NCT04115748
Filgotinib	Other	Phase PHASE1	Rheumatoid Arthritis	COMPLETED	NCT04608344
Rosuvastatin	Other	Phase PHASE1	Rheumatoid Arthritis	COMPLETED	NCT04608344
Pravastatin	Other	Phase PHASE1	Rheumatoid Arthritis	COMPLETED	NCT04608344
Atorvastatin	Other	Phase PHASE1	Rheumatoid Arthritis	COMPLETED	NCT04608344
[14C]-GLPG3667 capsule	Other	Phase PHASE1	Healthy	COMPLETED	NCT05335447
[14C]-GLPG3667 solution for infusion	Other	Phase PHASE1	Healthy	COMPLETED	NCT05335447
GLPG3667 capsule	Other	Phase PHASE1	Healthy	COMPLETED	NCT05335447
Placebo	Other	Phase PHASE3	Idiopathic Pulmonary Fibrosis	TERMINATED	NCT03733444
GLPG1690	Other	Phase PHASE3	Idiopathic Pulmonary Fibrosis	TERMINATED	NCT03733444
Placebo	Other	Phase PHASE3	Idiopathic Pulmonary Fibrosis	TERMINATED	NCT03711162
GLPG1690	Other	Phase PHASE3	Idiopathic Pulmonary Fibrosis	TERMINATED	NCT03711162
Adalimumab	Other	Phase PHASE4	Rheumatoid Arthritis	UNKNOWN	NCT05502731
Filgotinib	Other	Phase PHASE4	Rheumatoid Arthritis	UNKNOWN	NCT05502731
Intestinal ultrasound	Other	Preclinical	Ulcerative Colitis	UNKNOWN	NCT05653791
JAK inhibitor treatment	Drug	Approved	Colitis, Ulcerative	RECRUITING	NCT05456412
Placebo	Other	Phase PHASE2	Ulcerative Colitis	COMPLETED	NCT04577794
GLPG3970	Other	Phase PHASE2	Ulcerative Colitis	COMPLETED	NCT04577794
Placebo	Other	Phase PHASE2	Primary Sjögren Syndrome	TERMINATED	NCT04700280
GLPG3970	Other	Phase PHASE2	Primary Sjögren Syndrome	TERMINATED	NCT04700280
Placebo	Other	Phase PHASE3	Crohn's Disease	COMPLETED	NCT02914561
Filgotinib	Other	Phase PHASE3	Crohn's Disease	COMPLETED	NCT02914561
placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT01130818
GLPG0492	Other	Phase PHASE1	Healthy	COMPLETED	NCT01130818
Standard of Care	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT03926195
Placebo	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT03926195
Filgotinib	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT03926195
Filgotinib	Other	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT02065700
Placebo	Other	Phase PHASE3	Crohn's Disease	TERMINATED	NCT02914600
Filgotinib	Other	Phase PHASE3	Crohn's Disease	TERMINATED	NCT02914600
Placebo	Other	Phase PHASE2	Autosomal Dominant Polycystic Kidney Disease	TERMINATED	NCT04578548
GLPG2737	Other	Phase PHASE2	Autosomal Dominant Polycystic Kidney Disease	TERMINATED	NCT04578548
Itraconazole	Other	Phase PHASE1	Healthy	COMPLETED	NCT05272683
GLPG3667	Other	Phase PHASE1	Healthy	COMPLETED	NCT05272683
Nintedanib	Other	Phase PHASE1	Healthy	COMPLETED	NCT04971746
GLPG4716	Other	Phase PHASE1	Healthy	COMPLETED	NCT04971746
Pirfenidone	Other	Phase PHASE1	Healthy	COMPLETED	NCT04971746
Placebo	Other	Phase PHASE1	Healthy	COMPLETED	NCT04856358
GLPG3121	Other	Phase PHASE1	Healthy	COMPLETED	NCT04856358
GLPG3970	Other	Phase PHASE1	Healthy	COMPLETED	NCT04720183
Sulfasalazine	Other	Phase PHASE1	Healthy	COMPLETED	NCT04720183
GLPG3970 capsule	Other	Phase PHASE1	Healthy	COMPLETED	NCT04106297
Placebo oral solution	Other	Phase PHASE1	Healthy	COMPLETED	NCT04106297
GLPG3970 oral solution	Other	Phase PHASE1	Healthy	COMPLETED	NCT04106297
GLPG3667 capsules	Other	Phase PHASE1	Healthy	COMPLETED	NCT04097938
Placebos	Other	Phase PHASE1	Healthy	COMPLETED	NCT04097938
GLPG3667 oral suspension	Other	Phase PHASE1	Healthy	COMPLETED	NCT04097938
Placebo	Other	Phase PHASE3	Ulcerative Colitis	TERMINATED	NCT05479058
Filgotinib	Other	Phase PHASE3	Ulcerative Colitis	TERMINATED	NCT05479058
Standard of Care	Other	Phase PHASE2	Inflammatory Bowel Disease	TERMINATED	NCT03201445
Placebo	Other	Phase PHASE2	Inflammatory Bowel Disease	TERMINATED	NCT03201445
Filgotinib	Other	Phase PHASE2	Inflammatory Bowel Disease	TERMINATED	NCT03201445
Synovial Biopsy	Other	Approved	Rheumatoid Arthritis	COMPLETED	NCT07000890
50 patients will have a Free Choice between Filgotinib and anti TNF	Other	Phase PHASE4	Rheumatoid Arthritis	RECRUITING	NCT04985435
Anti-Tumor Necrosis Factor Alpha Drug (Product)	Drug	Phase PHASE4	Rheumatoid Arthritis	RECRUITING	NCT04985435
Filgotinib	Other	Phase PHASE4	Rheumatoid Arthritis	RECRUITING	NCT04985435
Placebo	Other	Phase PHASE2	Systemic Lupus Erythematosus	ACTIVE_NOT_RECRUITING	NCT05856448
GLPG3667	Other	Phase PHASE2	Systemic Lupus Erythematosus	ACTIVE_NOT_RECRUITING	NCT05856448
Placebo	Other	Phase PHASE2	Dermatomyositis	ACTIVE_NOT_RECRUITING	NCT05695950
GLPG3667	Other	Phase PHASE2	Dermatomyositis	ACTIVE_NOT_RECRUITING	NCT05695950
GLPG CAR T-cell therapy	Drug	Phase PHASE3	Hematological Malignancies	RECRUITING	NCT06652633
GLPG5101	Other	Phase PHASE1	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	ACTIVE_NOT_RECRUITING	NCT06561425
GLPG CAR T-cell therapy	GENETIC	Phase PHASE3	Hematological Malignancies	RECRUITING	NCT06652633
GLPG5101	GENETIC	Phase PHASE1	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	ACTIVE_NOT_RECRUITING	NCT06561425
JAK inhibitor treatment	OTHER	Approved	Colitis, Ulcerative	RECRUITING	NCT05456412
[14C]-GLPG3667 capsule	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT05335447
[14C]-GLPG3667 solution for infusion	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT05335447
GLPG3667 capsule	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT05335447
50 patients will have a Free Choice between Filgotinib and anti TNF	BEHAVIORAL	Phase PHASE4	Rheumatoid Arthritis	RECRUITING	NCT04985435
Anti-Tumor Necrosis Factor Alpha Drug (Product)	DRUG	Phase PHASE4	Rheumatoid Arthritis	RECRUITING	NCT04985435
Nintedanib	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04971746
GLPG4716	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT05030857
Pirfenidone	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04971746
[14]GLPG3970 oral solution	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04907149
[14C]GLPG3970 solution for infusion	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04907149
GLPG3121	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04856358
Sulfasalazine	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04720183
GLPG3970 tablet	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04708184
GLPG1205 capsules	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04704739
[14C]-GLPG1205 solution for infusion	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04704739
GLPG1205 film-coated tablets	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04704739
Placebo film-coated tablet	DRUG	Phase PHASE1	Systemic Lupus Erythematosus	TERMINATED	NCT04700267
GLPG3970 film-coated tablet	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04907149
GLPG4399 capsules	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04653467
GLPG4399 oral suspension	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04653467
Rosuvastatin	DRUG	Phase PHASE1	Rheumatoid Arthritis	COMPLETED	NCT04608344
Pravastatin	DRUG	Phase PHASE1	Rheumatoid Arthritis	COMPLETED	NCT04608344
Atorvastatin	DRUG	Phase PHASE1	Rheumatoid Arthritis	COMPLETED	NCT04608344
GLPG3667	DRUG	Phase PHASE2	Systemic Lupus Erythematosus	ACTIVE_NOT_RECRUITING	NCT05856448
GLPG3970	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04720183
GLPG4059 tablet	DRUG	Phase PHASE1	Healthy	TERMINATED	NCT04575818
GLPG4059 oral suspension	DRUG	Phase PHASE1	Healthy	TERMINATED	NCT04575818
Placebo to Match Filgotinib	DRUG	Phase PHASE3	Ankylosing Spondylitis	WITHDRAWN	NCT04483700
GLPG1972 - C	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04137341
GLPG1972 - B	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04137341
GLPG1972 - A	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04137341
[14C]-GLPG1972 oral solution	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04136327
[14C]-GLPG1972 solution for infusion	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04136327
GLPG1972 film-coated tablets	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04136327
GLPG3970 capsule	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04106297
Placebo oral solution	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04106297
GLPG3970 oral solution	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04708184
GLPG3667 capsules	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04097938
Placebos	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04097938
GLPG3667 oral suspension	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04097938
Placebo MAD	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03899909
GLPG3121 MAD	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03899909
Placebo SAD	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03899909
GLPG3121 SAD	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03899909
GLPG3312 FE MR	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03800472
GLPG3312 MR	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03800472
GLPG3312 IR	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03800472
[14C]-GLPG1690 capsules	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03787186
[14C]-GLPG1690 solution for infusion	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03787186
GLPG1690 film-coated tablets	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03787186
MOR106	DRUG	Phase PHASE2	Atopic Dermatitis	TERMINATED	NCT03864627
MOR 106	DRUG	Phase PHASE2	Atopic Dermatitis	TERMINATED	NCT03568071
GLPG2222	DRUG	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03540524
GLPG2451 dose regimen B	DRUG	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03540524
GLPG2451 dose regimen A	DRUG	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03540524
Voriconazole	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03515382
Itraconazole	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT05272683
GLPG2737	DRUG	Phase PHASE2	Autosomal Dominant Polycystic Kidney Disease	TERMINATED	NCT04578548
GLPG2737 multiple dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03410979
GLPG2737 single dose	DRUG	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03450720
GLPG1972 cohort 3	DRUG	Phase PHASE1	Osteoarthritis	COMPLETED	NCT03311009
GLPG1972 cohort 2	DRUG	Phase PHASE1	Osteoarthritis	COMPLETED	NCT03311009
GLPG1972 cohort 1	DRUG	Phase PHASE1	Osteoarthritis	COMPLETED	NCT03311009
Combined Placebo multiple dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03214614
GLPG2451/GLPG2222 multiple dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03214614
GLPG2451 multiple dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03214614
Prednisone	DRUG	Phase PHASE2	Noninfectious Uveitis	TERMINATED	NCT03207815
Standard of Care	DRUG	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT03926195
GLPG1972	DRUG	Phase PHASE2	Osteoarthritis	COMPLETED	NCT03595618
GLPG1690	DRUG	Phase PHASE2	Systemic Sclerosis	TERMINATED	NCT03976648
GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067/GLPG2222/GLPG2737 multiple dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067/GLPG2222 Placebo multiple dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067/GLPG2222 multiple dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067 oral tablet	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067 oral suspension	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03128606
Placebo multiple dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03214614
GLPG3067 multiple dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03128606
GLPG3067 single dose	DRUG	Phase PHASE1	Cystic Fibrosis	COMPLETED	NCT03589313
GLPG2222 400 mg	DRUG	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03119649
GLPG2222 200 mg	DRUG	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03119649
GLPG2222 100 mg	DRUG	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03119649
GLPG2222 50 mg	DRUG	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03119649
GLPG1205 250 loading dose and 50mg q.d. maintenance dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03102567
Placebo oral capsule	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03102567
GLPG1205 50mg q.d.	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03102567
Placebo Oral Tablet	DRUG	Phase PHASE2	Ankylosing Spondylitis	COMPLETED	NCT03117270
filgotinib	DRUG	Phase PHASE2	Psoriatic Arthritis	TERMINATED	NCT03320876
Tirabrutinib placebo	DRUG	Phase PHASE2	Sjogren's Syndrome	COMPLETED	NCT03100942
Filgotinib placebo	DRUG	Phase PHASE2	Cutaneous Lupus Erythematosus	COMPLETED	NCT03134222
Lanraplenib placebo	DRUG	Phase PHASE2	Cutaneous Lupus Erythematosus	COMPLETED	NCT03134222
Tirabrutinib	DRUG	Phase PHASE2	Sjogren's Syndrome	COMPLETED	NCT03100942
Lanraplenib	DRUG	Phase PHASE2	Cutaneous Lupus Erythematosus	COMPLETED	NCT03134222
GLPG2222 300 mg q.d.	DRUG	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03045523
GLPG2222 150 mg q.d.	DRUG	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT03045523
PTM filgotinib	DRUG	Phase PHASE3	Ulcerative Colitis	COMPLETED	NCT02914522
Placebo to match adalimumab	DRUG	Phase PHASE3	Psoriatic Arthritis	TERMINATED	NCT04115748
Adalimumab	DRUG	Phase PHASE4	Rheumatoid Arthritis	NOT_YET_RECRUITING	NCT05502731
Placebo to match MTX	DRUG	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02886728
MTX	DRUG	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02889796
csDMARDs	DRUG	Phase PHASE3	Rheumatoid Arthritis	COMPLETED	NCT02873936
Placebo to match filgotinib	DRUG	Phase PHASE3	Psoriatic Arthritis	TERMINATED	NCT04115839
GLPG1972 600 mg oral tablet fed	DRUG	Phase PHASE1	Osteoarthritis	COMPLETED	NCT02851485
GLPG1972 600 mg oral tablet fasted	DRUG	Phase PHASE1	Osteoarthritis	COMPLETED	NCT02851485
GLPG1972 600 mg oral solution fasted	DRUG	Phase PHASE1	Osteoarthritis	COMPLETED	NCT02851485
GLPG2451 single dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02788721
Placebo multiple intravenous administrations	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02739009
MOR106 multiple ascending doses, intravenous	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02739009
Placebo single ascending doses, intravenous	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02739009
MOR106 single ascending doses, intravenous	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02739009
Placebo QD	DRUG	Phase PHASE2	Idiopathic Pulmonary Fibrosis	COMPLETED	NCT02738801
GLPG1690 600 mg QD	DRUG	Phase PHASE2	Idiopathic Pulmonary Fibrosis	COMPLETED	NCT02738801
GLPG1837 dose 3	DRUG	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT02707562
GLPG1837 dose 2	DRUG	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT02707562
GLPG1837 dose 1	DRUG	Phase PHASE2	Cystic Fibrosis	COMPLETED	NCT02707562
GLPG2222 multiple doses	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02662452
GLPG2222 single dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02662452
Cocktail of CYP450 substrates	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02623296
GLPG1972 multiple ascending doses	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02612246
GLPG1972 single ascending doses	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02612246
GLPG1837 1000 mg	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02562950
GLPG1837 500 mg	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02562950
500 mg GLPG1837 as oral tablet	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02562859
500 mg GLPG1837 as oral suspension	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02562859
GLPG1205	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT04532567
Placebo multiple doses	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02662452
GLPG1837 multiple ascending doses	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02325037
Placebo single dose	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT03410979
GLPG1837 single ascending doses	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02325037
100 mg GLPG1205	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02143856
GLPG0634 100mg capsule once a day for 10 days	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01665924
GLPG0555 nanosuspension	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01278095
GLPG0555 solid dispersion	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01278095
GLPG1690, multiple ascending doses, oral suspension	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02179502
Placebo single ascending doses	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02179502
GLPG1690 single ascending doses	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02179502
GLPG0634 200 mg	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02162355
GLPG0634 100 mg	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02162355
GLPG0634 50 mg	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02162355
Filgotinib	DRUG	Phase PHASE1	Bioavailability	COMPLETED	NCT06043739
200 mg GLPG0634 as tablets, fed	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01915667
200 mg GLPG0634 as tablets, fasted	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01915667
200 mg GLPG0634 as capsules, fasted	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01915667
Placebo, multiple ascending doses, oral suspension	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT02179502
GLPG1205, multiple ascending doses, oral suspension	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01887106
Placebo single ascending doses, oral suspension	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01887106
GLPG1205 single ascending doses, oral suspension	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01887106
100 mg dose of [14C] GLPG0634	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01820806
Midazolam	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT05030857
GLPG0187 prodrug	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01580644
GLPG0974	DRUG	Phase PHASE2	Ulcerative Colitis	COMPLETED	NCT01829321
GLPG0778	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01336244
GLPG0259 free base	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01322451
GLPG0259 fumarate	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01322451
Placebo (Part B)	DRUG	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01211249
GLPG0259 (Part B)	DRUG	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01211249
GLPG0259 oral capsule	DRUG	Phase PHASE2	Rheumatoid Arthritis	COMPLETED	NCT01211249
GLPG0555 aqueous	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01208753
GLPG0634	DRUG	Phase PHASE1	Renal Impairment	COMPLETED	NCT02084199
GLPG0492	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01538420
Methylprednisolone	DRUG	Phase PHASE2	Acute Exacerbation of Remitting Relapsing Multiple Sclerosis	TERMINATED	NCT01039103
PEG-liposomal prednisolone sodium phosphate	DRUG	Phase PHASE2	Acute Exacerbation of Remitting Relapsing Multiple Sclerosis	TERMINATED	NCT01039103
GLPG0259 solution	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01024517
GLPG0555	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01208753
Methotrexate	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT00989703
Placebo	DRUG	Phase PHASE2	Systemic Lupus Erythematosus	ACTIVE_NOT_RECRUITING	NCT05856448
GLPG0187	DRUG	Phase PHASE1	Solid Tumors	COMPLETED	NCT01313598
placebo	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01336244
GLPG0259	DRUG	Phase PHASE1	Healthy	COMPLETED	NCT01024517

Total products: 491